NEW YORK, March 28, 2017 /PRNewswire/ --
Global regenerative medicines market is projected to reach $30,237 million by 2022, according to a report published by Allied Market Research. Regenerative medicines have the ability to repair, replace, and regenerate tissues and organs affected due to injury, disease, or natural ageing process. These medicines are capable of restoring the functionality of cells & tissues and are applicable in a wide range of degenerative disorders such as dermatology, neurodegenerative diseases, cardiovascular and orthopedic applications. This sector has garnered more attention in recent years thanks to technological advancements in tissue and organ regeneration. In addition, increased prevalence of chronic diseases, trauma emergencies, the potential of nanotechnology, and emergence of stem cell technology, have also played key roles. RepliCel Life Sciences Inc. (OTC: REPCF) (TSX-V: RP), Integra Lifesciences Holdings Corporation (NASDAQ: IART), MiMedx Group Inc. (NASDAQ: MDXG),
Baxter International Inc. (NYSE: BAX), Acorda Therapeutics Inc. (NASDAQ: ACOR)
The report also indicates that, "North America is the most attractive region in the global regenerative medicines market and is expected to be the first preference for new entrants due to the increasing end-use applications in the region. The North American regenerative medicines market is in its growing phase and is expected to exhibit high potential in future." This is partially due to favorable regulatory and reimbursement policies for tissue engineering, which show the interest of governments in the need for regenerative products.
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX-V: RP) is a RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal tissue healing and function. The Company's product pipeline is comprised of three clinical-stage products: RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 hair restoration. RCH-01 is under exclusive license by Shiseido Company for certain Asian countries.
Today RepliCel Life Sciences reported, "Compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use of RepliCel's type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis.
The clinical trial met its goal of establishing a complete safety profile at six months and showed no serious adverse events related to the study treatment or injection procedure. Additionally, each of the treated participants, all of whom suffered chronic tendon pain and loss of function over an extended period of time with no recovery from standard treatments, showed numerous clinically important improvements by various measures including tendon composition, blood supply, physical function and pain sensation.
"Chronic tendinosis is a state of tendon degeneration that is very difficult to reverse as is borne out by the many therapies and modalities that are used to try and treat it," stated Dr. Ross Davidson, an orthopedic surgeon, former clinical professor at the Department of Orthopaedics at the University of British Columbia, and past head physician and orthopaedic consultant for the Vancouver Canucks (of the National Hockey League (NHL)).
"This study shows exciting clinical improvements in patients with clinically diagnosed chronic Achilles tendinosis who were unresponsive to standard treatments, and who had suffered for many months (in some cases, years) with frequent pain and loss of function. Not only did the study show several clinically important improvements in pain and function scores, but several ultrasound measures clearly demonstrate a marked improvement in tendon structure; something rarely seen in patients with this condition," said Davidson.
"With further clinical studies, this new technology could represent a cutting-edge advancement in kick-starting a healing process that results in tendon regeneration. For the first time, we may have a treatment that shows signs of reversing the underlying problem, versus just treating the symptoms. This could be a game-changer in sports medicine," Dr. Davidson concluded.
Global medical technology company, Integra Lifesciences Holdings Corporation (NASDAQ: IART), announced that they have entered into an exclusive distribution agreement. Under the agreement, Dr. Reddy's will market and distribute DuraGen Plus® and Suturable DuraGen® Dural Regeneration Matrices for use in patients in India. M. V. Ramana, Executive Vice President and Head of Emerging Markets & India Business, Dr. Reddy's Laboratories said, "We are delighted to partner with Integra LifeSciences. With the launch of DuraGen, we look forward to building our presence in the segment of regenerative technologies and making a difference to the lives of patients undergoing neurosurgery." The DuraGen product line offers Duraplasty Solutions™ meant for the repair of the dura mater. Dura mater is a thick membrane that surrounds the brain and spinal cord, and contains the cerebrospinal fluid.
MiMedx Group Inc. (NASDAQ: MDXG) is an integrated developer, processor and marketer of patent protected and proprietary regenerative biopharmaceutical and biomaterial products processed from donated placental tissues. "Innovations in Regenerative Medicine" is the framework behind the company's mission to give physicians products and tissues to help the body heal itself. MiMedx process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. Their proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. The company is the leading supplier of placental tissue, having supplied over 800,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Baxter International Inc. (NYSE: BAX) through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.
Biotechnology company that focuses on therapies for spinal cord injury, multiple sclerosis and related nervous system disorders, Acorda Therapeutics Inc. (NASDAQ: ACOR) has patents on its neuregulin products. The neuregulins are a class of naturally-occurring protein growth factors, which have multiple effects on the nervous system and potential therapeutic applications in central nervous system disorders and cardiac indications. Growth factors are proteins that bind to receptors on the cell surface, with the primary result of activating cellular survival, proliferation and/or differentiation. Many growth factors are quite versatile, stimulating cellular division in numerous different cell types; while others are specific to a particular cell-type.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information:
Media Contact: firstname.lastname@example.org, +1-877-601-1879